BRAF p.Val600Glu (V600E) testing for assessment of treatment options in metastatic colorectal cancer

PLoS Currents

Volumn , Issue OCT, 2010, Pages

  Lea, Andrew ^a   Allingham Hawkins, Diane ^b   Levine, Susan ^c  

^a Hayes Inc   (New Zealand)

^b Hayes Inc   (Canada)

^c Health Technology Research and Consulting   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951947484     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1187     Document Type: Article

References (47)

1. American Cancer Society (ACS) [website]. Cancer Facts & Figures 2009. 2009. Available at: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2009.asp. Accessed September 23, 2010.
2. National Cancer Institute (NCI) [website]. Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets. Cancer: Colon and Rectum. 2010. Available at: http://seer.cancer.gov/statfacts/html/colorect.html. Accessed September 23, 2010.
3. National Cancer Institute (NCI) [website]. Colon Cancer Treatment (PDQ®). Modified August 19, 2009. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/colon/healthprofessional/allpages. Accessed September 23, 2010.
4. National Cancer Institute (NCI) [website]. Rectal Cancer Treatment (PDQ®). Modified August 23, 2010. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/rectal/healthprofessional/allpages. Accessed September 23, 2010.
5. National Comprehensive Cancer Network (NCCN) [website]. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. V.1.2011. September 10, 2010. Available at http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf. Accessed September 23, 2010.
6. National Comprehensive Cancer Network (NCCN) [website]. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. V.1.2011. September 10, 2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed September 23, 2010.
7. Amgen Inc. [website]. Vectibix® (panitumumab) Prescribing Information. May 2010. Available at http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed September 23, 2010.
8. Bristol-Myers Squibb and ImClone Systems [website]. ERBITUX® (Cetuximab). March 2010. Available at http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed September 23, 2010.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15;357(20):2040-8. PubMed PMID: 18003960.
10. Kyoto Encyclopedia of Genes and Genomes (KEGG) [website]. MAPK signaling pathway-Homo sapiens (human). February 4, 2010. Available at: http://www.genome.jp/kegg/pathway/hsa/hsa04010.html. Accessed September 23, 2010.
11. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. Epub 2009 Sep 8. Review. PubMed PMID: 19738166; PubMed Central PMCID: PMC2758310.
12. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008 Mar 13;358(11):1160-74. Review. Erratum in: N Engl J Med. 2009 Apr 9;360(15):1579. PubMed PMID: 18337605.
13. Food and Drug Administration (FDA) [website]. Center for Drug Evaluation and Research (CDER). Cetuximab (Erbitux) and Panitumumab (Vectibix). Updated January 11, 2010. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm. Accessed September 23, 2010.
14. Online Mendelian Inheritance in Man (OMIM) [website]. V-raf murine sarcome viral oncogene homolog B1, BRAF (*164757). Updated May 19, 2010. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=164757.Accessed September 23, 2010.
15. Ensembl [website]. Transcript: BRAF-001 (ENST00000288602). August 2010. Available at: http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000157764;r=7:140424943-140624564;t=ENST00000288602. Accessed September 23, 2010.
16. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005 Jul 15;65(14):6063-9. PubMed PMID: 16024606.
17. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009 Dec 10;27(35):5931-7. Epub 2009 Nov 2. PubMed PMID: 19884549.
18. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010 Jul 15;127(2):367-80. PubMed PMID: 19908233.
19. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 4;101(3):465-72. Epub 2009 Jul 14. PubMed PMID: 19603024; PubMed Central PMCID: PMC2720232.
20. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer. 2010 Jun 8;102(12):1762-8. Epub 2010 May 18. PubMed PMID: 20485284; PubMed Central PMCID: PMC2883698.
21. Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci. 2010 Aug;55(8):2352-6. Epub 2010 Mar 19. PubMed PMID: 20300843.
22. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010 Jul 15;127(2):367-80. PubMed PMID: 19908233.
23. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010 Feb 1;16(3):790-9. Epub 2010 Jan 26. PubMed PMID: 20103678.
24. Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010 May;17(5):1429-34. Epub 2010 Jan 5. PubMed PMID: 20049644.
25. ARUP Laboratories [website]. BRAF codon 600 Mutation Detection by Pyrosequencing: 2002498. 2010. Available at: http://www.aruplab.com/guides/ug/tests/2002498.jsp. Accessed September 23, 2010.
26. ARUP Laboratories [website]. KRAS Mutation Detection with BRAF reflex: 2001932. 2010. Available at: http://www.aruplab.com/guides/ug/tests/2001932.jsp. Accessed September 23, 2010.
27. Laboratory Corporation of America (LabCorp) [website]. Test Menu [search: BRAF]. 2010. Available at: https://www.labcorp.com/wps/portal/provider/testmenu. Accessed September 23, 2010.
28. Mayo Medical Laboratories [website]. Unit Code 87980: BRAF Mutation Analysis (V600E), Tumor. 2010. Available at: http://www.mayomedicallaboratories.com/test-catalog/Overview/87980. Accessed September 23, 2010.
29. Quest Diagnostics Inc. [website]. BRAF Mutation Analysis (16767). 2010. Available at: http://www.questdiagnostics.com/hcp/testmenu/jsp/showTestMenu.jsp?fn=16767.html&labCode=PHP. Accessed September 23, 2010.
30. Quest Diagnostics Inc. [website]. EGFR Pathway (KRAS with Reflex to NRAS, BRAF) (16819). 2010. Available at: http://www.questdiagnostics.com/hcp/testmenu/jsp/showTestMenu.jsp?fn=16819.html&labCode=PHP. Accessed September 23, 2010.
31. UNC Health Care McLendon Clinical Laboratories [website]. Molecular Genetics Laboratory. Modified November 9, 2009. Available at: http://labs.unchealthcare.org/forms/braf.pdf. Accessed September 23, 2010.
32. Vanderbilt Pathology Laboratory Services [website]. Test Directory. BRAF(V600E)(V6A). 2010. Available at: http://www.mc.vanderbilt.edu/root/vumc.php?test_id=896&doc=24499&site=vpls. Accessed September 23, 2010.
33. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008 Apr;40(3):295-8. PubMed PMID: 18428050.
34. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, Hartmann A, Zwarthoff EC. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One. 2010 Jan 21;5(1):e8802. PubMed PMID: 20098682; PubMed Central PMCID: PMC2809099.
35. Bentivegna S, Zheng J, Namsaraev E, Carlton VE, Pavlicek A, Moorhead M, Siddiqui F, Wang Z, Lee L, Ireland JS, Suyenaga K, Willis TD, Faham M, Seymour AB. Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum Mutat. 2008 Mar;29(3):441-50. PubMed PMID: 18186519.
36. Packham D, Ward RL, Ap Lin V, Hawkins NJ, Hitchins MP. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol. 2009 Jun;18(2):62-71. PubMed PMID: 19430299.
37. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn. 2009 Mar;11(2):140-7. Epub 2009 Feb 12. PubMed PMID: 19213871; PubMed Central PMCID: PMC2665863.
38. Jakubauskas A, Griskevicius L. KRas and BRaf mutational status analysis from formalin-fixed, paraffinembedded tissues using multiplex polymerase chain reaction-based assay. Arch Pathol Lab Med. 2010 Apr;134(4):620-4. PubMed PMID: 20367313.
39. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 Aug 18;101(4):715-21. Epub 2009 Jul, 14, PubMed PMID: 19603018; PubMed Central PMCID: PMC2736831.
40. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009 Oct 2;4(10):e7287. PubMed PMID: 19806185; PubMed Central PMCID: PMC2750753.
41. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008 Dec 10;26(35):5705-12. Epub 2008 Nov 10. PubMed PMID: 19001320.
42. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009 Jan;20(1):84-90. Epub 2008 Jul 31. PubMed PMID: 18669866.
43. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009 Dec 10;27(35):5924-30. Epub 2009 Nov 2. PubMed PMID: 19884556.
44. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008 May;7(3):184-90. PubMed PMID: 18621636.
45. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. PubMed PMID: 10655437.
46. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010 Aug;11(8):753-62. Epub 2010 Jul 8. PubMed PMID: 20619739.
47. Mao C, Liao RY, Chen Q. BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. Epub 2010 Jun 1. PubMed PMID: 20514492.